Linezolid-Induced Thrombocytopenia Is Caused by Suppression of Platelet Production via Phosphorylation of Myosin Light Chain 2

Masataka Tajima, Yoshinori Kato, Jun Matsumoto, Iori Hirosawa, Mariko Suzuki, Yuki Takashio, Mao Yamamoto, Yoshifumi Nishi, and Harumi Yamada

Department of Pharmaceutical Sciences, International University of Health and Welfare; 2600–1 Kita-kanemaru, Ohtawara, Tochigi 324–8501, Japan; and Graduate School of Pharmaceutical Sciences, International University of Health and Welfare; 2600–1 Kita-kanemaru, Ohtawara, Tochigi 324–8501, Japan.

Received May 25, 2016; accepted August 17, 2016

Linezolid (LZD) is an antimicrobial that is commonly used for treatment of vancomycin-resistant Enterococci and methicillin-resistant Staphylococcus aureus infections. However, the development of thrombocytopenia, one of the most frequent adverse side effects of this antimicrobial, can lead to discontinuation of LZD treatment. While clinical studies indicate that risk factors for the development of LZD-induced thrombocytopenia include treatment for >14 consecutive days, renal dysfunction, and chronic liver disease, the fundamental mechanism governing the pathogenesis of this disorder remains unclear. In this study, we aimed to elucidate the mechanism of LZD-induced thrombocytopenia by investigating the impact of LZD treatment on platelet destruction and production using rat platelet-rich plasma (PRP) and human immortalized cell lines, respectively. Compared to the control population, an increase in lactate dehydrogenase release was not detected upon exposure of rat PRP to varying concentrations of LZD, indicating that this compound is not cytotoxic towards platelets. Meanwhile, LZD treatment resulted in a significant dose-dependent increase in the proliferation of HEL human erythroleukemia and MEG-01 human megakaryoblast cells, respectively, and/or prevent this disease.

Key words: thrombocytopenia; linezolid; adverse effect; mechanism; myosin light chain

Linezolid (LZD), a member of the oxazolidinone class of antibacterial agents, exhibits a high level of clinical efficacy against vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). LZD functions by binding the 50S ribosomal subunit, thereby inhibiting the formation of a functional 70S initiation complex. Due to this unique mechanism of action, there is thought to be no cross-resistance between LZD and other conventional antibiotics. Furthermore, LZD is expected to maintain its therapeutic efficacy in tissues associated with poor blood flow (e.g., bronchoalveolar lavage, inflammatory fluid, bone, fat, muscle, and cerebrospinal fluid), making it an ideal option for treatment of deep-tissue infections.

Lastly, as the bioavailability of LZD is approximately 100%, it is possible to switch from intravenous to oral administration while using the same dosage. Although these advantages make LZD an excellent antimicrobial agent, administration of LZD has been reported to cause adverse side effects such as gastrointestinal disturbances, thrombocytopenia, decreased hemoglobin/hematocrit levels, and cutaneous reactions. Of these, the incidence of thrombocytopenia is particularly high (7.4–64.7%), and the onset of this condition can lead to the discontinuation of LZD treatment. Recent clinical studies demonstrated that risk factors for LZD-induced thrombocytopenia include treatment for >14 consecutive days, renal dysfunction, and chronic liver disease.

The primary causes of thrombocytopenia can be broadly categorized into two mechanisms: increased consumption/destruction or reduced production of platelets. For example, while heparin and quinine are known to cause thrombocytopenia by accelerating platelet destruction via an immunologic reaction, chemotherapeutic agents such as gemcitabine, cisplatin, and carboplatin decrease platelet production via myelosuppression. Although LZD induces myelosuppression, this compound is more frequently associated with thrombocytopenia than pancytopenia. Furthermore, few reports have indicated that administration of LZD results in stimulation of the immune response. While the fundamental mechanism governing LZD-induced thrombocytopenia remains unclear, it is likely that LZD induces thrombocytopenia by affecting the consumption/destruction and/or production of platelets.

In this study, to elucidate the mechanism of LZD-induced thrombocytopenia, direct platelet cytotoxicity was measured using rat platelet-rich plasma (PRP), and the impact of LZD on platelet production was investigated using human erythrocytes and megakaryoblast cell lines.

**MATERIALS AND METHODS**

**Materials**

LZD, menadione (MEN), and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma-Aldrich Corp. (St. Louis, MO, U.S.A.), and panobinostat (PAN) was purchased from LC Labs. (Woburn, MA, U.S.A.). Polyclonal rabbit anti-myosin light chain 2 (MLC2), polyclonal rabbit anti-phospho-MLC2, and goat anti-rabbit immunoglobulin G (IgG) horseradish peroxidase (HRP)-linked antibodies were purchased from LC Labs. (St. Louis, MO, U.S.A.). Other reagents were purchased from Sigma-Aldrich Corp. (St. Louis, MO, U.S.A.) and Nacalai Tesque Inc. (Kyoto, Japan).
purchased from Cell Signaling Technology (Danvers, MA, U.S.A.). The cytotoxicity detection kit and the Cell Counting Kit-8 were purchased from Roche Diagnostic Corp. (Basel, Switzerland) and Dojindo Laboratories (Kumamoto, Japan), respectively. ISOGEN was purchased from Nippon Gene, Co. (Tokyo, Japan). The high-capacity cDNA synthesis kit and Power SYBR Green PCR Master Mix were purchased from Applied Biosystems (Waltham, MA, U.S.A.). Pierce BCA Protein Assay kit was purchased from Thermo Scientific (Waltham, MA, U.S.A.). Primers were purchased from Invitrogen Corp. (Waltham, MA, U.S.A.). All other reagents were of the highest grade commercially available.

**Animals** Eight-week-old male Wistar-ST rats were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Rats were housed under a 12 h light/dark cycle and given food and water *ad libitum* for 1 week for acclimatization. The present study was approved by the Experimental Animal Care and Use Committee of the International University of Health and Welfare.

**Preparation of PRP** PRP was prepared using a previously published procedure, but with modifications. Briefly, blood was collected from the abdominal vena cava of rats after diethyl ether-induced anesthesia using a syringe containing 3.8% sodium citrate [9:1 dilution (v/v) of blood: 3.8% sodium citrate], and PRP was obtained by centrifugation at 150×*g* for 15 min at room temperature. PRP was diluted 40-fold in suspension buffer [134 mM NaCl, 2.9 mM KCl, 1.0 mM MgCl₂, 10.0 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 5.0 mM glucose, 12.0 mM NaHCO₃, 0.34 mM Na₂HPO₄, and 0.3% bovine serum albumin (BSA) (pH 7.4)] and the platelet concentration was adjusted to approximately 7.4×10⁷ platelets/mL.

**Measurement of Lactate Dehydrogenase (LDH) Leakage from Platelets** The cytotoxicity of LDH was determined by measuring the release of LDH from platelets. For these analyses, diluted PRP was incubated with 0–200 μM LZD or with 40 μM MEN (positive control), which disrupts platelets, at least in part, via oxidative damage, for 4 h at 37°C. Subsequently, LDH leakage from platelets was measured using a cytotoxicity detection kit, according to the manufacturer’s instructions. Briefly, 100 μL of sample was added to 100 μL of reaction mixture and then incubated for 10 min at room temperature. After incubation, 50 μL of stop solution was added, and the absorbance of the mixture at 490 nm was measured using a microplate reader (SH-1000 Lab; Corona Electric Co., Ltd., Hitachinaka, Japan). Total LDH activity was determined using platelets disrupted by incubation in lysis solution, and the level of LDH leakage was expressed as a percentage of total activity.

**Cell Culture** The human erythroleukemia cell line (HEL) and the MEG-01 human megakaryoblastic cell line were obtained from the Japanese Collection of Research Biological Resources (JCRB) Cell Bank (Osaka, Japan). Cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum (FBS), 10000 U/mL penicillin, and 10000 μg/mL streptomycin at 37°C in a humidified 5% CO₂ incubator.

**Cell Proliferation Assay** HEL and MEG-01 cells were seeded in 96-well plates at 5×10⁴ cells/well and treated with 0–400 μM LZD for 3 d. After incubation, 10 μL of cell-counting kit-8 was added to each well. The plates were then incubated for 2 h at 37°C and the absorbance of each well at 450 nm was measured using a microplate reader.

**Cell Differentiation and Total RNA Extraction** The mRNA expression levels of GPIIIa and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were measured using the following primers: GPIIIa forward 5’-GGT TCC TGCTCT CAGTGA TGTG-3’, GPIIIa reverse 5’-GAATTCTTT TCGTCT GGTGA A-3’, GAPDH forward 5’-GAAGGT GAAGGT CCG AGT CT-3’, GAPDH reverse 5’-GAAGGTAGTG TATG GATTCT-3’. PCR reactions were carried out in 96-well PCR plates and were comprised of 12.5 μL of Power SYBR Green PCR Master Mix, 1.5 μL of each primer (5 pmol/μL), 2 μL of cDNA in TE buffer solution, and 7.5 μL of RNase-free water. The thermocycler conditions were as follows: denaturation at 95°C for 15 s, annealing at 56°C for 30 s, and elongation at 72°C for 30 s. The fluorescence intensity of the amplification process was monitored using 7300 sequence detection system software (Applied Biosystems). The GPIIIa mRNA levels were normalized against that of GAPDH.

**Western Blot Analyses** MEG-01 cells were treated with 0–200 μM LZD or 20 nM PAN (positive control) for 24 h and total protein was extracted according to the method described by Bishton et al. Briefly, cells were rinsed with phosphate buffered saline (PBS) and lysed by suspension in Triton X lysis buffer [20 mM Tris (pH 7.4), 135 mM NaCl, 1.5 mM MgCl₂, 1 mM ethylene glycol tetraacetic acid (EGTA), 10% glycerol, and 1% Triton X-100] containing protease and phosphatase inhibitors for 30 min on ice. Lysates were then centrifuged at 12000×*g* for 15 min at 4°C and supernatants were harvested. Protein concentrations were measured using the Pierce BCA Protein Assay kit with BSA as the standard. Proteins were separated by 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using the Laemmli method, and electro phosphorytated to polyvinylidene fluoride (PVDF) membranes. Membranes were blocked by incubation with 2% BSA in Tris-buffered saline containing 0.1% Tween 20 (TBS-Tween) for 1 h at room temperature, and then incubated with a primary antibody specific to phosphorylated MLC (phospho-MLC; 1:500) or to total MLC (1:1000) in 2% BSA TBS-Tween at 4°C overnight. After washing with TBS-Tween, membranes were incubated with a peroxidase-conjugated anti-rabbit IgG secondary antibody for 1 h at room temperature. After again washing with TBS-Tween, membranes were incubated with the enhanced chemiluminescence (ECL) plus detection reagent and visualized using a ChemiDoc XRS device (Bio-Rad, Hercules, CA, U.S.A.). Band-intensities were
analyzed with Quantity One software (Bio-Rad).

**Statistical Analysis** Data are expressed as the mean±standard deviations (S.D.) or standard errors (S.E.). Dunnett’s test for multiple comparisons was utilized to assess the statistical significance of differences between results. *p*<0.05 was considered significant for all tests.

**RESULTS**

**LZD Does Not Exert Cytotoxic Effects on Platelets** To investigate the cytotoxic effects of LZD toward platelets, rat PRP samples were exposed to different concentrations of LZD and cytotoxicity was evaluated by measuring LDH leakage levels. Plasma typically contains small amounts of LDH, which is spontaneously released from various tissues or hematopoietic cells, resulting in a baseline level of LDH activity. Indeed, the untreated control group exhibited approximately 5% LDH activity compared to the 100% lysis control. While treatment with MEN (positive control) resulted in complete disruption of the platelets, none of the LZD concentrations tested induced LDH leakage from the PRP samples (Fig. 1), indicating that LZD was not cytotoxic towards platelets.

**LZD Enhances Proliferation, but Does Not Affect Differentiation, of HEL and MEG-01 Cells** We next investigated the impact of LZD on the proliferation of HEL and MEG-01 cells and on differentiation in the platelet production process. LZD treatment resulted in a dose-dependent increase in HEL cell proliferation, with the cells exposed to a high dose (200 µM) of LZD exhibiting a 90% increase in proliferation compared to the control group (Fig. 2). Likewise, the proliferation of MEG-01 cells was increased by LZD treatment.

Meanwhile, treatment with PMA resulted in increased GPIIIα mRNA expression in both HEL and MEG-01 cells compared to the control, which was accompanied by differentiation into mature megakaryocytes (Fig. 3). Notably, these GPIIIα expression levels were not affected by LZD treatment during differentiation.

**LZD Increases Phosphorylation of MLC2 on MEG-01 Cells** Several studies suggest that proplatelet formation is regulated by the Rho/Rho-associated protein kinase (ROCK) pathway, and that MLC2 plays a critical role in this process.22,24 Therefore, to investigate the impact of LZD on the development of proplatelets from megakaryocytes, MLC2 phosphorylation levels were measured in LZD-treated MEG-01 cells via Western blot analysis. PAN was previously reported to significantly increase MLC2 phosphorylation in MEG-01 cells and was therefore utilized as a positive control.22 LZD treatment resulted in a dose-dependent increase in MLC2 phosphorylation, and cells exposed to a high concentration (200 µM) of LZD exhibited similar levels of MLC2 phosphorylation as the PAN-treated control cells (Fig. 4). Furthermore, while treatment with 20 µM of LZD did not result in a statistically significant increase in MLC2 phosphorylation, there was a trend towards increased phosphorylation in this population.

---

**Fig. 1. Effect of Linezolid (LZD) on the Release of Lactate Dehydrogenase (LDH) from Platelets in Rat Platelet-Rich Plasma (PRP)**

PRP samples were treated with or without LZD (2–200 µM) for 4h. Menadione (MEN; 40 µM) was used as a positive control. Each value is expressed as a percentage of total activity. The data are expressed as the mean±S.E. of the results from five experiments using five animals each. Dunnett’s test was utilized for analyses of statistical significance. ***p<0.001 indicates a significant difference from the control group.

**Fig. 2. Effect of LZD on the Proliferation of HEL and MEG-01 Cells**

HEL and MEG-01 cells were treated with or without LZD (2–400 µM) for 3d. Each value is expressed as a percentage of the control group (100%). Data are expressed as the mean±S.D. of the results from five experiments using five animals each. Dunnett’s test was utilized for analyses of statistical significance. **p<0.01 and ***p<0.001 indicate significant differences from the control group.
Platelets are produced from hematopoietic stem cells (HSCs) via various biological processes. HSCs differentiate in a stepwise fashion as follows: from the burst-forming units erythroid/megakaryocytes (BFU-E/M) to colony-forming unit megakaryocytes (CFU-MK), megakaryoblasts, and megakaryocytes. After maturation, megakaryocytes produce and subsequently release proplatelets. Released platelets then circulate in the bloodstream for 7–10 d and are trapped within the liver and spleen. Platelet numbers are maintained by modulation of the production and destruction processes, and enhanced consumption/destruction or reduced production of platelets results in the development of thrombocytopenia. We therefore hypothesized that the mechanism of LZD-induced thrombocytopenia is due to one or both of these effects.

First, we investigated the impact of LZD on platelet destruction by measuring the level of LDH leakage from platelets in rat PRP upon treatment with varying concentrations of LZD. In the clinical setting, patients with VRE and MRSA infections are treated with 600 mg LZD twice daily. When healthy volunteers received this dosage, the maximum steady state plasma concentration ($C_{\text{max}}$) was approximately 60 µM. In contrast, patients with renal dysfunction that received this dosage reached a $C_{\text{max}}$ of 200 µM and developed thrombocytopenia. In this study, we therefore chose to utilize a maximum LZD concentration of 200 µM; however, even at this concentration LZD was not cytotoxic towards platelets, indicating that the clinical application of this antimicrobial does not enhance platelet destruction.

Next, we focused on examining the effects of LZD on the in vitro proliferation and differentiation of erythroleukemia/megakaryoblastic cells, which are the intermediate steps of the platelet production process, using the HEL and MEG-01 cell lines. Previous studies demonstrated that HEL cells can be induced to differentiate into megakaryocytic or erythroid...
cells via PMA or hemin treatment, respectively.\textsuperscript{30,31} Thus, HEL cells can be regarded as the corresponding BFU-E/M. Meanwhile, MEG-01 cells, which can be considered differentiated megakaryoblasts, can also be induced to differentiate into megakaryocytes upon treatment with PMA, resulting in the production of platelet-like particles.\textsuperscript{32} This PMA-mediated differentiation of HEL and MEG-01 cells is accompanied by an increase in the expression level of the megakaryocyte marker GPIIIa. Notably, we observed an LZD concentration-dependent increase in the proliferation of both cell lines upon exposure to LZD (Fig. 2); however, there were no differences in the GPIIIa mRNA expression levels of cells treated with PMA alone and those co-treated with LZD and PMA (Fig. 3), indicating that LZD does not affect the differentiation of these cell lines. These data therefore suggest that LZD-induced thrombocytopenia is not due to a defect in the proliferation/differentiation of BFU-E/M and megakaryoblasts during platelet production.

Finally, we investigated the effect of LZD on platelet release, the final step of the platelet production process. Phosphorylation of MLC2, which is regulated by Rho guanosine 5’-triphosphatase (GTPase) family protein and their effector, such as RhoA, Cdc42, Rac1, PAC1 and ROCK1, is a critical step in this process,\textsuperscript{22,24} and increased MLC2 phosphorylation results in suppression of platelet release. PAN is a histone deacetylase inhibitor used for treatment of hematologic cancers. Notably, the primary adverse side effect of this compound is the induction of thrombocytopenia resulting from the suppression of platelet release via increased MLC2 phosphorylation.\textsuperscript{22} We therefore assessed the effect of LZD treatment on MLC2 phosphorylation in MEG-01 cells by Western blot analysis. Consistent with previous findings,\textsuperscript{22} MLC2 phosphorylation was upregulated in the presence of PAN (Fig. 4). Likewise, LZD treatment resulted in a dose-dependent increase in MLC2 phosphorylation, with cells treated with 200 µM of LZD exhibiting a 3.1-fold increase in MLC2 phosphorylation compared to that of the control group. These findings therefore suggest that, similar to PAN, LZD induces thrombocytopenia by suppressing platelet release via an increase in MLC2 phosphorylation.

LZD exhibits excellent tissue penetration. Indeed, in a previous study, the penetration efficacy of LZD into bone and muscle was 60 and 94%, respectively, at 20 min post-infusion.\textsuperscript{49} Meanwhile, Komatsu \textit{et al.} reported LZD penetration efficacies of 88 and 84% into the bone marrow and iliopectoral muscles of rabbits, respectively, at 0.33 h post-injection.\textsuperscript{49} Moreover, the LZD concentration was reported to be 1.6-fold higher in the cerebrospinal fluid than in the plasma of patients with central nervous system infections.\textsuperscript{59} Based on these reports, it was predicted that LZD would rapidly distribute into bone marrow, and at nearly the same concentration as in plasma, and thereby inhibit platelet production by increasing MLC2 phosphorylation. Indeed, we found that enhanced MLC phosphorylation occurred at 20 µM of LZD, which was markedly less than the $C_{\text{max}}$ achieved in healthy volunteers receiving 600 mg LZD.

The action mechanism of LZD to increase MLC2 phosphorylation in MEG-01 cell remains unknown. However, considering from several reports, megakaryocyte might express organic anionic transporter polypeptide (OATP) 2B1,\textsuperscript{34} which mediate uptake of LZD.\textsuperscript{35} Intracellular LZD might act as reported in PAN, which induce acetylation of tubulin\textsuperscript{36} or reduce the protein expression of CDC42, Rac1, and RhoA.\textsuperscript{22} Also, the intracellular signaling pathways that cause the increase of MLC phosphorylation contain Cdc42/Rac1/PAK pathway via MLC kinase, and Rho/Rock pathway via myosin phosphatase.\textsuperscript{22,24} Further study about the action mechanism of LZD in MEG-01 cell and the relevance of these pathways is considered necessary for the elucidation of LZD-induced thrombocytopenia.

In conclusion, the results presented here suggest that LZD has no direct effect on platelet destruction, but rather induces thrombocytopenia via the suppression of platelet release from mature megakaryocytes, which is the final step in the platelet production process. Our findings may facilitate the development of strategies to treat and/or prevent LZD-induced thrombocytopenia.

Acknowledgment We would like to thank Editage for providing English language editing.

Conflict of Interest The authors declare no conflict of interest.

REFERENCES


